CDXS - Codexis GAAP EPS of -$0.17 beats by $0.04 revenue of $21.32M in-line
2023-08-03 16:31:33 ET
- Codexis press release ( NASDAQ: CDXS ): Q2 GAAP EPS of -$0.17 beats by $0.04 .
- Revenue of $21.32M (-44.5% Y/Y) in-line.
-
2023 Financial Guidance
Codexis reiterated its 2023 financial guidance issued on July 20, 2023, as follows:
- Product revenues are expected to be in the range of $30 million to $35 million, excluding enzyme sales related to PAXLOVID™.
- R&D revenues are expected to be in the range of $21 million to $24 million.
- Gross margin on product revenue is expected to be in the range of 55% to 65%.
For further details see:
Codexis GAAP EPS of -$0.17 beats by $0.04, revenue of $21.32M in-line